Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 4Gastrointestinal 4Breast 4Thoracic 3Tumor-Agnostic 2Sarcoma 2Genitourinary 2Plasma cell 1Other solid neoplasm 1Head & Neck 1Dermatologic 1

Conditions

Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

Cisplatin 263Radiotherapy 166Cetuximab 159Docetaxel 105Fluorouracil 104pembrolizumab 94Radiotherapy, Intensity-Modulated 83Carboplatin 80Paclitaxel 73Nivolumab 59Erlotinib Hydrochloride 35Surveys and Questionnaires 32Gemcitabine 32durvalumab 30Radiation 29Drug Therapy 25Immunohistochemistry 21Gefitinib 21Capecitabine 21tremelimumab 18Bevacizumab 18Surgical Procedures, Operative 17Sorafenib 17Magnetic Resonance Spectroscopy 17Ipilimumab 17Pemetrexed 16lenvatinib 15atezolizumab 15Radiosurgery 15Gene Expression Profiling 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × saracatinib × Head & Neck × Clear all
NCT00513435 2014-04-30

Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Completed
9 enrolled 8 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡